Amylyx Refocuses On Avexatide As LUCIDITY Milestone Raises Stakes [Yahoo! Finance]
Amylyx Pharmaceuticals, Inc. (AMLX)
Company Research
Source: Yahoo! Finance
Amylyx Pharmaceuticals has completed recruitment for its pivotal Phase 3 LUCIDITY trial of Avexatide for post bariatric hypoglycemia. The company is shifting its core focus toward Avexatide while preparing for a potential expedited regulatory submission once top line data are available later this year. Amylyx has also nominated AMX318, a GLP 1 antagonist, as a new development candidate and is refining its broader pipeline. Amylyx Pharmaceuticals (NasdaqGS:AMLX) is drawing attention as the market weighs this shift in focus and the importance of the LUCIDITY trial. The stock trades at $14.11, and the 1 year return of 368.8% contrasts with a weaker 3 year record, which shows a 60.7% decline. Year to date, the share price is up 23.6%, while shorter term moves over 7 and 30 days have been more muted, with declines of 4.1% and 1.3% respectively. For investors watching clinical and pipeline catalysts, the combination of a fully enrolled pivotal trial and a fresh GLP 1 antagonist can
Show less
Read more
Impact Snapshot
Event Time:
AMLX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
AMLX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
AMLX alerts
High impacting Amylyx Pharmaceuticals, Inc. news events
Weekly update
A roundup of the hottest topics
AMLX
News
- Amylyx Pharmaceuticals Inc (AMLX) Q4 2025 Earnings Call Highlights: Strategic Advances and ... [Yahoo! Finance]Yahoo! Finance
- Amylyx Pharmaceuticals (AMLX) had its price target raised by HC Wainwright from $28.00 to $34.00. They now have a "buy" rating on the stock.MarketBeat
- Amylyx Pharmaceuticals Says 2026 Could Be “Transformative” Ahead of Avexitide Phase 3 Readout [Yahoo! Finance]Yahoo! Finance
- Amylyx Pharmaceuticals, Inc. Q4 2025 Earnings Call Summary [Yahoo! Finance]Yahoo! Finance
- Amylyx Pharmaceuticals Q4 Earnings Call Highlights [Yahoo! Finance]Yahoo! Finance
AMLX
Earnings
- 3/3/26 - In-Line
AMLX
Sec Filings
- 3/4/26 - Form 4
- 3/4/26 - Form 4
- 3/4/26 - Form 4
- AMLX's page on the SEC website